AZD1390

DRUG6 trials

Conditions

Brain Neoplasms, MalignantGlioblastomaGlioblastoma MultiformeGliomaGlioma, MalignantLeptomeningeal Disease (LMD)Metastatic CancerMetastatic Solid Tumor

Early Phase 1

AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients

Active, not recruitingNCT05182905

Nader SanaiGlioblastoma, Glioblastoma Multiforme, Glioma +1

Start: 2022-05-27End: 2026-12-10Target: 97Updated: 2026-03-09

Phase 1

A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

RecruitingNCT03423628

AstraZenecaBrain Neoplasms, Malignant, Leptomeningeal Disease (LMD), Primary Glioblastoma Multiforme +1

Start: 2018-04-02End: 2026-09-16Target: 180Updated: 2025-12-22

A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC

RecruitingNCT04550104

University of LeedsNon Small Cell Lung Cancer

Start: 2021-03-17End: 2028-03-31Target: 200Updated: 2025-12-19

A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer

Active, not recruitingNCT05678010

Memorial Sloan Kettering Cancer CenterMetastatic Cancer, Metastatic Solid Tumor, Metastatic Tumor +3

Start: 2023-05-17End: 2028-05-17Target: 54Updated: 2025-05-18

Phase 2

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

RecruitingNCT03970447

Global Coalition for Adaptive ResearchGlioblastoma

Start: 2019-07-30End: 2030-06-01Target: 2250Updated: 2026-04-03

GBM AGILE Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent Glioblastoma (GBM)

RecruitingCTIS2024-511452-40-00

Global Coalition For Adaptive Research Inc.Oncology - Glioblastoma (GBM)

Start: 2025-09-12Target: 120Updated: 2025-09-12

Neuro-Oncology2025-11-01

Update on GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.

Journal of Clinical Oncology2025-05-281 citations

LTBK-02. EVALUATION OF PAXALISIB IN GBM AGILE PHASE 3 REGISTRATION PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA

Neuro-Oncology2024-11-012 citations

CTIM-16. SAFETY AND PRELIMINARY EFFICACY OF AZD1390 + RADIATION THERAPY FOR GLIOBLASTOMA

Neuro-Oncology2024-11-011 citations

CTNI-39. UPDATE ON GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA

Neuro-Oncology2024-11-01

CTNI-55. A PHASE 0/1B STUDY OF AZD1390 PLUS RADIOTHERAPY IN NEWLY DIAGNOSED, MGMT-UNMETHYLATED AND RECURRENT GLIOBLASTOMA PATIENTS

Neuro-Oncology2024-11-01

OS09.7.A GBM AGILE PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GBM: RESULTS OF FIRST EXPERIMENTAL ARM, REGORAFENIB

Neuro-Oncology2024-10-012 citations

JS02.5.A A PHASE 0/1B STUDY OF AZD1390 PLUS RADIOTHERAPY IN RECURRENT GLIOBLASTOMA PATIENTS

Neuro-Oncology2024-10-011 citations

KS03.5.A EVALUATION OF VAL-083 IN GBM AGILE, A PHASE 3 REGISTRATION PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA

Neuro-Oncology2024-10-01

P27.11.A GLOBAL EXPANSION OF GBM AGILE: A PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA

Neuro-Oncology2024-10-01

Evaluation of VAL-083 in GBM AGILE, a phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma.

Journal of Clinical Oncology2024-06-011 citations

Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors

Communications Medicine2024-05-216 citations

Abstract CT044: A phase 0/1b study of AZD1390 plus radiotherapy in newly-diagnosed, MGMT-unmethylated glioblastoma patients

Cancer Research2024-04-05

Abstract IA006: Multifaceted effects of DNA damage response inhibitors on radiation responses of glioblastoma and the normal brain

Cancer Research2024-01-09

Modulatory Potential of Poly (ADP‐Ribose) Polymerase 1 (PARP1) in BRCA‐Mutated Tumors

European Journal of Cancer Care2024-01-011 citations

CTNI-85. GBM AGILE PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GBM: RESULTS OF FIRST EXPERIMENTAL ARM, REGORAFENIB

Neuro-Oncology2023-11-0117 citations

CTNI-25. A PHASE 0/1B STUDY OF AZD1390 PLUS RADIOTHERAPY IN RECURRENT GLIOBLASTOMA PATIENTS

Neuro-Oncology2023-11-011 citations

P11.29.B UPDATE ON GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA

Neuro-Oncology2023-09-01

Immune profiling in patients with glioblastoma treated with VT1021 in a phase I/II expansion study.

Journal of Clinical Oncology2023-06-013 citations

Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system

Neuro-Oncology Advances2023-01-0117 citations

12 more papers not shown

AZD1390

Sponsors

Conditions

Early Phase 1

Phase 1

Phase 2

Related Papers